Shots:

• Lilly’s partner Junshi has dosed the first healthy volunteer in a study evaluating JS016 to combat COVID-19. The study is being conducted by Junshi in China while Lilly to imminently initiate its P-I study in the US
• Both P-I studies aim to evaluate the safety- tolerability- PK and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19. Lilly has exclusive rights in the ROW and will begin dosing patients in a complementary P-I study in the US imminently
• The initiation of the clinical trial follows the P-I clinical study of LY-CoV555 which is currently being tested in hospitalized COVID-19 patients. Additionally- Lilly is planning to evaluate the efficacy of JS016 as both a monothx. and a combination with other Ab treatments in COVID-19 patients. The cocktails will include JS016 & LY-CoV555- as well as other Abs- currently in preclinical development

Click here to read full press release/ article 

Ref: Eli Lilly | Image: Eli Lilly